Electroconvulsive Therapy (ECT): Modern Practice, Efficacy, Cognitive Effects, Informed Consent, and Clinical Indications

Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe major depressive disorder and one of the most rigorously studied interventions in all of psychiatry. Despite decades of stigma — fueled in part by its historical misuse and inaccurate media portrayals — modern ECT bears little resemblance to its mid-20th-century predecessor. Contemporary practice involves general anesthesia, neuromuscular blockade, precise stimulus dosing, and sophisticated physiological monitoring, making it a safe and well-tolerated procedure with a mortality rate comparable to that of general anesthesia alone (approximately 1 per 73,000–80,000 treatments).

The American Psychiatric Association (APA), the National Institute for Health and Care Excellence (NICE), the Royal College of Psychiatrists, and the World Federation of Societies of Biological Psychiatry (WFSBP) all endorse ECT as a first-line or early-line treatment for specific clinical scenarios. Globally, an estimated 1–2 million patients receive ECT annually, though utilization varies dramatically by country, region, and local regulatory environment. In the United States, estimates suggest approximately 100,000 individuals receive ECT each year, with the highest utilization among adults aged 45–64 with treatment-resistant depression, catatonia, or psychotic mood episodes.

This article provides an in-depth clinical review of ECT's mechanisms, efficacy data, cognitive effects, indications, and the evolving landscape of informed consent and patient rights. It is intended for clinicians, trainees, and educated readers seeking a thorough, evidence-based understanding of this essential psychiatric intervention.

ECT was introduced in 1938 by Italian neuropsychiatrists Ugo Cerletti and Lucio Bini, who observed that electrically induced seizures could produce remission in patients with severe psychosis and catatonia. During its first three decades, ECT was administered without anesthesia or muscle relaxation, frequently at high and unmonitored doses, and sometimes punitively in institutional settings. These practices caused significant morbidity — including vertebral fractures, prolonged confusion, and substantial retrograde amnesia — and rightly drew ethical condemnation.

The modern era of ECT began in the 1960s–1970s with the introduction of short-acting general anesthetics (methohexital, later propofol), succinylcholine for neuromuscular blockade, and the development of brief-pulse stimulus waveforms. The shift from sine-wave to brief-pulse (0.5–1.5 ms pulse width) stimulation in the 1980s reduced total electrical charge delivered to the brain by 50–70%, dramatically decreasing cognitive side effects while preserving efficacy. More recently, ultrabrief-pulse (0.3 ms) right unilateral ECT has further reduced cognitive burden, as demonstrated by the landmark work of Sackeim and colleagues (2008) and the PRIDE study group.

The 1990 APA Task Force Report and its 2001 update established comprehensive procedural standards, patient selection guidelines, and informed consent frameworks that define current best practices. Subsequent NICE guidelines (2003, updated 2009) and WFSBP recommendations (2010) have further refined indications and practice parameters.

Despite over 80 years of clinical use, the precise mechanisms underlying ECT's therapeutic effects are not fully elucidated, though converging lines of evidence implicate multiple neurobiological systems.

Neurotransmitter Systems

ECT produces widespread effects on monoaminergic neurotransmission. Preclinical and human studies demonstrate that repeated ECT sessions downregulate postsynaptic β-adrenergic receptors and upregulate 5-HT_1A serotonin receptor sensitivity, effects that parallel those of chronic antidepressant treatment but occur more rapidly. ECT also enhances dopaminergic transmission in mesolimbic circuits, which may explain its efficacy in psychotic depression and catatonia. GABAergic tone increases progressively across an ECT course, reflected in the well-documented rise in seizure threshold over successive treatments — a phenomenon termed the anticonvulsant hypothesis of ECT action proposed by Sackeim (1999).

Neuroplasticity and Neurotrophic Factors

A robust body of evidence links ECT efficacy to enhanced neuroplasticity. Preclinical models show that electroconvulsive stimulation (ECS) upregulates brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex. Meta-analyses of human studies (Brunoni et al., 2014) confirm that serum BDNF levels increase significantly after an ECT course, and that this increase correlates with clinical improvement. ECT is one of the only treatments demonstrated to increase hippocampal volume in humans, as shown by multiple MRI studies (Nordanskog et al., 2010; Oltedal et al., 2018 — the Global ECT-MRI Research Collaboration, or GEMRIC, study involving 281 patients). The GEMRIC study reported bilateral hippocampal volume increases averaging 2–5% following ECT, with increases correlated to clinical response in some but not all analyses.

Neuroendocrine and Immune Effects

ECT normalizes hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, a hallmark of severe depression. Dexamethasone suppression test normalization following ECT predicts sustained remission. ECT also modulates inflammatory markers: meta-analyses show reductions in interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) after treatment, consistent with the neuroinflammatory hypothesis of depression.

Functional Connectivity and Network Effects

Resting-state functional MRI studies reveal that ECT modulates connectivity within and between the default mode network (DMN), the salience network, and the cognitive control network. Specifically, ECT appears to reduce DMN hyperconnectivity — a neuroimaging signature of depressive rumination — and normalize anterior cingulate cortex (ACC) activity. The dorsolateral prefrontal cortex–subcortical circuit, implicated in executive dysfunction and anhedonia, also shows restored connectivity following successful ECT courses.

Genetic Factors

Pharmacogenomic research on ECT response is in early stages. Variants in the BDNF Val66Met polymorphism, 5-HTTLPR serotonin transporter gene, and genes encoding GABA_A receptor subunits have been investigated as potential predictors of ECT response, but no single genetic variant has been reliably validated. A 2019 genome-wide association study (GWAS) by Sigström et al. identified suggestive loci but no genome-wide significant hits, underscoring the polygenic and complex nature of ECT response.

ECT is indicated across a range of psychiatric and neuropsychiatric conditions, with the strength of evidence varying by diagnosis.

Primary Indications (Strong Evidence)

• Major depressive disorder (MDD) — severe, with or without psychotic features: This is the most common indication. ECT is particularly effective for psychotic depression, where response rates reach 80–90% compared to approximately 50–55% for pharmacotherapy alone (Petrides et al., 2001). The DSM-5-TR identifies catatonic features, psychotic features, and treatment resistance as clinical contexts favoring ECT.
• Treatment-resistant depression (TRD): Conventionally defined as failure to respond to ≥2 adequate antidepressant trials, TRD affects approximately 30% of MDD patients. ECT achieves response rates of 50–70% and remission rates of 35–55% in treatment-resistant populations (Kellner et al., 2012 — the CORE/PRIDE research consortium).
• Bipolar depression and mania: ECT is effective for both depressive and manic phases of bipolar disorder, with response rates comparable to those in unipolar depression. It is a preferred option when rapid resolution is needed or when pharmacotherapy is limited by pregnancy, medical comorbidity, or medication intolerance.
• Catatonia: Regardless of etiology (mood disorder, psychotic disorder, general medical condition, or autism spectrum disorder), catatonia responds robustly to ECT. Response rates of 80–100% are reported in case series and retrospective studies. Benzodiazepines (lorazepam) are the first-line treatment, but ECT is indicated when benzodiazepine trials fail or when malignant catatonia (with autonomic instability, hyperthermia) requires emergent intervention.
• Acute suicidality: ECT produces rapid reduction in suicidal ideation, often within the first 1–3 sessions. The Kellner et al. (2005) study demonstrated that suicidal ideation resolved in 38% of patients after a single session and in 61% by session six, with a final remission rate of 81% for suicidal ideation by end of course. No other psychiatric treatment has demonstrated comparable speed of antisuicidal effect.

Secondary Indications (Moderate Evidence)

• Schizophrenia: ECT is not a primary treatment for chronic schizophrenia but has demonstrated efficacy as an augmentation strategy for clozapine-resistant schizophrenia. The Petrides et al. (2015) randomized trial showed that clozapine plus ECT was superior to clozapine alone, with a 50% response rate in the augmentation group versus 0% with clozapine continuation alone. ECT is also effective for acute exacerbations with prominent catatonic, affective, or positive psychotic symptoms.
• Neuroleptic malignant syndrome (NMS): ECT has been used successfully in NMS, particularly cases with overlapping catatonic features, though evidence comes primarily from case series.
• Parkinson's disease with comorbid depression or motor fluctuations: ECT improves both mood and motor symptoms, likely via enhanced dopaminergic transmission. Transient improvements in motor function are well-documented, though sustained motor benefit requires maintenance ECT.

Diagnostic Nuances and Pitfalls

Accurate diagnosis is essential because ECT response varies markedly by condition. Depression with melancholic features (psychomotor retardation, anhedonia, diurnal variation, weight loss) predicts better ECT response than depression characterized primarily by anxiety, personality disorder comorbidity, or chronic pain. Clinicians must distinguish treatment-resistant depression from pseudo-resistance due to inadequate medication dosing, poor adherence, undiagnosed bipolar disorder, or unrecognized medical contributors (hypothyroidism, sleep apnea, substance use). Failure to identify these factors leads to inappropriate ECT referral and predictable non-response.

ECT's efficacy is supported by the strongest evidence base of any treatment in psychiatry for acute depression.

Acute Efficacy

The UK ECT Review Group (2003) meta-analysis, encompassing 18 randomized controlled trials, found ECT significantly superior to sham ECT (standardized mean difference [SMD] = −0.91, 95% CI −1.27 to −0.54) and to pharmacotherapy (SMD = −0.80, CI −1.29 to −0.29). Remission rates in acute MDD range from 50–65% across meta-analyses, rising to 70–90% for psychotic depression and melancholic subtypes. The number needed to treat (NNT) for ECT versus sham for response in depression is approximately 3–4, and for ECT versus pharmacotherapy, approximately 4–6.

The CORE study (Petrides et al., 2001; Kellner et al., 2006) was a landmark multicenter trial demonstrating that optimized bilateral ECT achieved remission in 87% of patients with psychotic depression and 53% with non-psychotic depression, with remission defined as Hamilton Rating Scale for Depression (HRSD-24) score ≤10. This remains one of the highest remission rates documented for any psychiatric treatment in any condition.

Comparative Effectiveness

Head-to-head data comparing ECT with specific pharmacotherapy regimens are limited but informative:

• ECT vs. pharmacotherapy: The Folkerts et al. (1997) trial comparing ECT with the tricyclic antidepressant paroxetine in treatment-resistant depression found ECT response rates of 71% versus 28% for pharmacotherapy (p < 0.001).
• ECT vs. repetitive transcranial magnetic stimulation (rTMS): Multiple meta-analyses, including Mutz et al. (2019, The Lancet Psychiatry), confirm ECT's superiority over rTMS for acute depression, with ECT showing significantly higher remission rates (approximately 52% vs. 33%). However, rTMS has fewer cognitive side effects and is preferred for milder treatment-resistant cases.
• ECT vs. ketamine/esketamine: The landmark Anand et al. (2023) ELEKT-D trial, published in the New England Journal of Medicine, randomized 403 patients with TRD to ECT or intravenous ketamine (0.5 mg/kg, administered six times over three weeks). Non-inferiority of ketamine to ECT was established: remission rates were 55.4% for ECT and 56.0% for ketamine, with ketamine showing fewer cognitive side effects. This trial reshaped clinical discussions about first-choice neuromodulation for TRD, though it has been noted that the study used right unilateral ultrabrief-pulse ECT and may have included a less treatment-resistant population than typical ECT-referred cohorts.

Maintenance ECT and Relapse Prevention

Relapse following an acute ECT course is a major clinical challenge. Without continuation treatment, relapse rates reach 50–80% within six months. The CORE continuation study (Kellner et al., 2006) demonstrated that continuation pharmacotherapy with nortriptyline plus lithium reduced 6-month relapse to approximately 39%, compared to 84% with placebo. Maintenance ECT (m-ECT) — typically administered weekly, tapering to monthly over 6–12 months — achieves relapse rates of 30–40% at one year, comparable to or slightly better than continuation pharmacotherapy. The PRIDE study (Kellner et al., 2016) demonstrated that the combination of maintenance ECT plus pharmacotherapy (lithium plus venlafaxine) yielded the lowest 6-month relapse rate of approximately 20%, establishing combined continuation as the current gold standard for sustaining remission.

Cognitive side effects are the most clinically significant adverse effects of ECT and the primary concern for patients and clinicians. A nuanced understanding of these effects — their type, duration, severity, and modifiability — is essential for informed clinical decision-making.

Types of Cognitive Effects

• Postictal confusion: Occurs immediately after each treatment and typically resolves within 30–60 minutes. Duration and severity correlate with stimulus dose, electrode placement, and individual vulnerability.
• Anterograde amnesia: Difficulty forming new memories during the treatment course. This is generally transient and resolves within 1–4 weeks of completing ECT in most patients. Objective neuropsychological testing typically shows return to or improvement above baseline within this period.
• Retrograde amnesia: Impaired recall of events preceding the ECT course. This is the most persistent and distressing cognitive effect. Autobiographical memory — memory for personal life events — is more vulnerable than impersonal (semantic) memory. Most retrograde amnesia is temporally graded, affecting memories from weeks to months preceding treatment, with older memories relatively spared. However, some patients report persistent autobiographical memory gaps extending months or, rarely, years prior to treatment.

Modifying Factors

Cognitive effects are not uniform and are strongly influenced by treatment parameters:

• Electrode placement: Bilateral (bitemporal) ECT produces significantly more cognitive impairment than right unilateral (RUL) ECT, particularly at high stimulus doses. The Sackeim et al. (2008) landmark randomized trial established that high-dose (6× seizure threshold) RUL ultrabrief-pulse ECT achieved comparable efficacy to bilateral ECT with substantially less cognitive impairment.
• Pulse width: Ultrabrief-pulse (≤0.3 ms) ECT produces less cognitive disruption than standard brief-pulse (0.5–1.5 ms) ECT. Meta-analyses (Tor et al., 2015) confirm reduced retrograde amnesia with ultrabrief-pulse protocols, though efficacy may be slightly lower, requiring more sessions to achieve remission.
• Stimulus dose: Higher doses relative to seizure threshold produce greater cognitive effects. Suprathreshold dosing is necessary for efficacy (RUL ECT at 1× threshold is ineffective), but the optimal dose-to-threshold ratio balances efficacy against cognitive burden (typically 6× threshold for RUL, 1.5–2.5× for bilateral).
• Treatment frequency: Twice-weekly ECT produces fewer cognitive side effects than thrice-weekly, with comparable overall efficacy but a longer time to response.

Objective vs. Subjective Cognitive Outcomes

An important clinical tension exists between objective neuropsychological testing and subjective cognitive complaints. Most neuropsychological studies show that average cognitive performance returns to baseline or improves (due to depression-related cognitive impairment resolving) within 2–4 weeks post-ECT. However, a subset of patients — estimated at 10–25% depending on the study and assessment method — report persistent subjective memory difficulties. Semkovska and McLoughlin's (2010) comprehensive meta-analysis of 84 studies found no evidence of persistent objective cognitive deficits beyond 15 days post-ECT in most domains, but noted that autobiographical memory assessment tools used in research may lack sensitivity to detect real-world memory gaps. This discordance remains an active area of investigation and ethical discussion.

Modern ECT involves a standardized procedural protocol that maximizes safety and efficacy while minimizing adverse effects.

Pre-ECT Evaluation

A thorough pre-ECT workup includes psychiatric diagnostic confirmation, medical history review, physical examination, baseline cognitive assessment (using instruments such as the Montreal Cognitive Assessment [MoCA] or a brief autobiographical memory interview), baseline laboratory studies (complete blood count, basic metabolic panel, ECG), and anesthesia risk assessment. Neuroimaging (CT or MRI) is not routinely required but is indicated when intracranial pathology is suspected. The only absolute contraindication to ECT is raised intracranial pressure (e.g., from a space-occupying lesion without adequate decompression), as the transient increase in intracranial pressure during the seizure can precipitate herniation.

Anesthesia and Stimulus Delivery

General anesthesia is induced with a short-acting agent — methohexital (0.75–1.0 mg/kg) remains the gold standard, though propofol (1.0–1.5 mg/kg) is widely used despite mildly anticonvulsant properties that may shorten seizure duration. Succinylcholine (0.5–1.0 mg/kg) provides neuromuscular blockade to prevent musculoskeletal injury. Patients are pre-oxygenated and ventilated with 100% O₂ throughout. The electrical stimulus is delivered via electrodes applied to the scalp in one of several configurations:

• Right unilateral (RUL): d'Elia placement (right frontotemporal–right vertex). Preferred for most indications due to reduced cognitive effects.
• Bilateral (bitemporal, BT): Electrodes at both temporal regions. Used when rapid response is critical (severe suicidality, catatonic emergency, food/fluid refusal) or when RUL ECT has been insufficiently effective.
• Bifrontal (BF): Electrodes over both frontal regions. Some evidence suggests cognitive advantages over bitemporal placement with comparable efficacy, though data are less extensive.

Seizure Monitoring and Adequacy

Seizure threshold is determined at the first session using stimulus titration. Adequate seizures are typically ≥15–25 seconds of generalized electroencephalographic (EEG) activity, though seizure duration alone is a poor predictor of efficacy. EEG quality markers — including postictal suppression, seizure coherence, and amplitude — provide better indices of therapeutic seizure adequacy. Most acute ECT courses consist of 6–12 sessions, delivered 2–3 times weekly.

Informed consent for ECT represents one of the most thoroughly regulated consent processes in medicine, reflecting both the treatment's historical controversies and its significant cognitive risks.

Elements of Valid Consent

Adequate informed consent for ECT must include: (1) a clear explanation of the procedure, including anesthesia and stimulus delivery; (2) the clinical indication and expected benefits, with specific response and remission probability estimates; (3) a thorough discussion of cognitive side effects, including the possibility of persistent autobiographical memory loss; (4) a description of alternative treatments and their comparative efficacy; (5) the voluntary nature of consent and the right to withdraw at any time; and (6) the typical treatment course, including number and frequency of sessions.

Capacity and Involuntary ECT

Most ECT is administered with voluntary informed consent. However, clinical scenarios arise in which patients lack decision-making capacity — for example, in severe catatonia, psychotic depression with nihilistic delusions, or profound psychomotor retardation. Legal frameworks for involuntary ECT vary enormously by jurisdiction. In the United States, most states require court authorization or independent review for involuntary ECT, with some states imposing additional requirements such as agreement from two independent psychiatrists. In the United Kingdom, ECT without consent is governed by the Mental Health Act 1983 (as amended 2007), which requires a second opinion appointed doctor (SOAD) certification, except in emergencies.

Shared Decision-Making

Best practice involves shared decision-making that incorporates the patient's values, prior treatment experiences, and specific concerns about cognitive effects. Decision aids — standardized informational tools that present efficacy and risk data in accessible formats — have been developed and shown to improve patient knowledge and satisfaction with the consent process. The patient should be given adequate time to consider the information, ask questions, and involve family members or advocates if desired. Consent should be documented as an ongoing process, reaffirmed at regular intervals throughout the treatment course, not merely as a one-time signature.

Identifying patients most likely to benefit from ECT is a major research priority. Clinical, neurobiological, and demographic predictors have been investigated extensively.

Positive Prognostic Factors

• Psychotic features: The strongest clinical predictor of ECT response. Patients with delusional depression consistently show the highest remission rates (80–95%).
• Melancholic features: Psychomotor retardation, anhedonia, early morning awakening, and appetite/weight loss predict favorable response.
• Shorter episode duration: Patients referred earlier in a depressive episode respond better than those with chronic (>2 years) episodes.
• Older age: Older adults often show higher ECT response rates than younger patients, potentially due to the higher prevalence of melancholic and psychotic depression in this age group, as well as age-related neurobiological factors.
• Previous ECT response: A history of prior favorable ECT outcome is among the strongest predictors of future response.

Negative Prognostic Factors

• Comorbid personality disorder: Particularly borderline personality disorder, which is associated with lower ECT response rates and higher relapse rates. Estimates suggest comorbid personality pathology reduces ECT remission rates by 20–30%.
• High degree of treatment resistance: While ECT is the most effective treatment for TRD, patients who have failed 5+ adequate medication trials show lower response rates (approximately 40–50%) compared to those with fewer prior failures (60–70%).
• Chronic depression (>2 years): Chronicity is consistently associated with poorer acute and long-term ECT outcomes.
• Comorbid substance use disorder: Active substance use diminishes ECT response and increases relapse risk.
• High pre-treatment anxiety: Prominent anxious features within a depressive episode are associated with reduced ECT efficacy in several studies.

Neurobiological Predictors

Emerging research identifies potential biomarkers of ECT response. Higher pre-treatment anterior cingulate cortex (ACC) activity on fMRI or EEG has been associated with better outcomes, paralleling findings in antidepressant and psychotherapy research. Lower pre-treatment hippocampal volume and greater hippocampal volume increase during ECT may predict response, though results are inconsistent across studies. The GEMRIC consortium continues to investigate structural and functional neuroimaging predictors in the largest ECT neuroimaging dataset assembled to date.

Patients referred for ECT typically present with complex clinical profiles. Understanding common comorbidities is essential for treatment planning and outcome prediction.

Psychiatric Comorbidities

• Anxiety disorders: Approximately 40–60% of patients receiving ECT for MDD have a comorbid anxiety disorder (generalized anxiety disorder, panic disorder, or PTSD). Comorbid anxiety is associated with a more protracted ECT course and modestly lower remission rates, though many patients experience substantial anxiety reduction alongside mood improvement.
• Personality disorders: Estimates of personality disorder comorbidity in ECT populations range from 20–40%, depending on assessment methodology. As noted, this comorbidity negatively affects outcomes.
• Substance use disorders: Approximately 10–20% of ECT-referred patients have a history of or current substance use disorder. Active substance use must be addressed concurrently for optimal ECT outcomes.
• Bipolar disorder: ECT is used in both bipolar depression and mania. The comorbidity of bipolar disorder with anxiety disorders (prevalence ~50–60%) and substance use (~30–40%) further complicates treatment planning in this population.

Medical Comorbidities

ECT-referred populations are often medically complex. Common medical comorbidities include cardiovascular disease (15–30%), diabetes mellitus (10–20%), and neurological conditions including dementia, Parkinson's disease, and epilepsy. ECT can be safely administered in most medical conditions with appropriate anesthetic management and specialist consultation. Relative medical contraindications — pheochromocytoma, unstable aneurysm, recent (within 3 months) cerebrovascular accident — require individualized risk-benefit assessment.

Notably, ECT in patients with pre-existing cognitive impairment (e.g., early-stage Alzheimer's disease with comorbid depression) requires careful monitoring, as these patients may experience more pronounced or prolonged cognitive side effects. However, successful treatment of depression in this population can produce net cognitive improvement by resolving the depressive pseudodementia component.

ECT's safety and efficacy have been evaluated across several important clinical populations that deserve specific discussion.

Pregnancy

ECT is considered one of the safest treatments for severe depression during pregnancy, particularly when psychotropic medications pose teratogenic risks. No increase in congenital anomalies has been attributed to ECT. Guidelines recommend fetal monitoring, left lateral positioning after the first trimester to avoid aortocaval compression, and obstetric standby for patients in the third trimester. A systematic review by Anderson and Reti (2009) documented that the incidence of complications (premature labor, vaginal bleeding) was low and generally attributable to the underlying psychiatric condition rather than the procedure itself.

Adolescents and Children

ECT is used in adolescents (typically age ≥13) for treatment-resistant depression, catatonia, and neuroleptic malignant syndrome. Efficacy data in adolescents, while less extensive than in adults, suggest response rates of 50–60% for depression and high response rates for catatonia. The APA and American Academy of Child and Adolescent Psychiatry (AACAP) provide guidelines for adolescent ECT, emphasizing that it should be reserved for cases of clear treatment resistance and administered only in centers with appropriate expertise. Legal requirements for consent often involve additional safeguards, including independent psychiatric evaluation and, in some jurisdictions, court approval.

Older Adults

Older adults represent the largest demographic group receiving ECT and often show excellent response rates. However, they are also at higher risk for cognitive side effects, post-treatment delirium, and cardiovascular complications. Right unilateral ultrabrief-pulse ECT is particularly advantageous in this population. Baseline cognitive assessment is critical for detecting pre-existing impairment and monitoring ECT-related changes.

Several important research questions remain at the frontier of ECT science.

Biomarker-Guided ECT

The search for reliable biomarkers that predict individual ECT response is a major research priority. Neuroimaging (structural MRI, functional connectivity), EEG-based indices (including machine learning analyses of pre-treatment EEG patterns), peripheral blood biomarkers (BDNF, inflammatory markers, cortisol), and genetic markers are all under active investigation. The GEMRIC consortium and multi-site studies such as the ongoing AFTER (Advancing Frontiers in Treatment with ECT Research) program aim to develop clinically usable predictive algorithms.

ECT vs. Novel Rapid-Acting Antidepressants

The ELEKT-D trial comparing ECT with ketamine represents only the beginning of comparative effectiveness research. Future studies are needed to compare ECT with intranasal esketamine (Spravato), psilocybin-assisted psychotherapy, and other emerging rapid-acting treatments. The field requires longer-term outcome data, cost-effectiveness analyses, and studies in populations with more severe treatment resistance than the ELEKT-D cohort.

Minimizing Cognitive Effects

Ongoing research into cognitive protection includes investigation of stimulus waveform optimization (amplitude-titrated ECT), pharmacological neuroprotective strategies (e.g., memantine co-administration, though results have been mixed), and novel electrode placements. The focal electrically administered seizure therapy (FEAST) approach, which uses an asymmetric electrode configuration to produce more focal seizure initiation, has shown promise in early-phase studies but requires larger trials.

Magnetic Seizure Therapy (MST)

MST uses transcranial magnetic stimulation at seizure-inducing intensities to produce seizures with more cortical and less deep-brain involvement than ECT. Theoretically, this could preserve efficacy while reducing cognitive side effects. Initial randomized data (Daskalakis et al., 2020) suggest that MST has comparable efficacy to ultrabrief-pulse RUL ECT with fewer cognitive side effects, but larger, definitive trials are needed.

Limitations of Evidence

Despite ECT's strong evidence base, significant limitations remain. Most RCTs are relatively small (n = 20–100), conducted at academic centers, and subject to methodological heterogeneity in electrode placement, dosing, and outcome measures. Sham-controlled trials are ethically difficult and uncommon in severely ill populations. Long-term outcome data beyond 6–12 months are sparse. Cognitive outcome research is hampered by inconsistent use of standardized neuropsychological batteries and the difficulty of disentangling depression-related cognitive impairment from treatment-related effects. Patient experience data, qualitative research, and real-world effectiveness studies are needed to complement the existing RCT evidence base.